安进公布去年第四季度业绩，营收同比增长9%至98.7亿美元，超过分析师平均预期的94.7亿美元；净利润同比暴增超112%至13.3亿美元，调整后每股收益为5.29美元，远超分析师预期的4.73美元。期内产品销售额增长7%，主要得益于产品销量增长10%。但部分增长被售价下降4%所抵消。展望今年，安进预计营收将在370亿至384亿美元之间，调整后每股收益将在21.6至23美元之间，对比分析师预期分别为371.9亿美元和20.63美元。此外，安进目前正在对实验性药物MariTide进行六项三期试验，涉及肥胖症及相关疾病，包括心脏病和睡眠呼吸暂停。安进还计划于今年启动针对2型糖尿病患者的Maritide三期临床研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.